Publications
Selective haematological cancer eradication with preserved haematopoiesis
An article published in the Nature on May 22, 2024
Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion
Poster showing that T cells expressing an engineered CD52 can be effectively shielded from Alemtuzumab-mediated depletion.
Base-Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression
Preclinical data presented during a poster session at the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California.
Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases
Preclinical data presented during a poster session at the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California.
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
An article published in the Journal of Experimental Medicine on September 29, 2023
Molecular Shielding of the Pan-Hematopoietic Marker CD45 May Enable a Targeted Universal Approach for Replacement of the Hematopoietic System
Data presented during a poster session at ASGCT on May 18, 2023, that describes key progress with shielded CD45 cells.
Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells From CD123 Targeted Immunotherapy
Data presented during a poster session at ASH on December 11, 2022, that describes key progress with shielded CD123 cells.
Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117-Targeted Immunotherapy in Vivo
Data presented during a poster session at ASH on December 11, 2022, that describes key progress with shielded CD117 cells.